Gilead Sciences SG&A decreased by 19.1% to $1.45B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.3%, from $1.26B to $1.45B. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 2.4% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalLower is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026May 7, 2026
How to read this metric
A rising ratio of SG&A to revenue may indicate inefficiency or aggressive expansion, while a falling ratio suggests improved operating leverage.
Detailed definition
Selling, general, and administrative expenses encompass the costs associated with the day-to-day operation of the busine...
Peer comparison
Standard operating expense category; peers with larger global sales forces typically show higher absolute SG&A levels.
Metric ID:
selling_general_and_administrativeHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.35B | $1.19B | $1.65B | $1.08B | $1.36B | $1.21B | $2.02B | $1.32B | $1.85B | $1.32B | $1.61B | $1.38B | $1.38B | $1.43B | $1.91B | $1.26B | $1.37B | $1.36B | $1.79B | $1.45B |
| QoQ Change | — | -11.9% | +38.7% | -34.4% | +25.3% | -10.6% | +66.5% | -34.7% | +40.2% | -28.9% | +22.3% | -14.5% | +0.1% | +4.1% | +33.1% | -34.0% | +8.5% | -0.6% | +32.2% | -19.1% |
| YoY Change | — | — | — | — | +0.4% | +1.9% | +22.4% | +21.8% | +36.3% | +8.4% | -20.4% | +4.2% | -25.5% | +9.0% | +18.6% | -8.5% | -0.9% | -5.3% | -5.9% | +15.3% |
Range$1.08B – $2.02B
CAGR+1.5%
Avg YoY Growth+4.5%
Median YoY Growth+3.1%
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $1.26B | $1.37B | $1.36B | $1.79B | $1.45B |
| Total | $1.26B | $1.37B | $1.36B | $1.79B | $1.45B |
SG&A at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's sg&a?
- Gilead Sciences (GILD) reported sg&a of $1.45B in Q1 2026.
- How has Gilead Sciences's sg&a changed year-over-year?
- Gilead Sciences's sg&a increased by 15.3% year-over-year, from $1.26B to $1.45B.
- What is the long-term trend for Gilead Sciences's sg&a?
- Over 4 years (2021 to 2025), Gilead Sciences's sg&a has grown at a 2.4% compound annual growth rate (CAGR), from $5.25B to $5.77B.
- What does sg&a mean?
- The overhead costs of running the business, including sales, marketing, and general corporate expenses.